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Introduction
Idiopathic dilated cardiomyopathy (DCM) is
characterized by a dilated and poorly contracting heart
and is of ill-defined cause.1,2 The prognosis for patients
with idiopathic DCM is poor.2–6 There is still no
effective medical therapy, and some patients progress
rapidly to death. Cardiac transplantation has become
a more successful treatment for idiopathic DCM in
children than conventional treatment.7 However, most
patients die while waiting for cardiac transplantation
because there are few donors in Taiwan. The purpose
of this study was to review our experience with pediatric
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patients diagnosed with idiopathic DCM and attempt
to discover prognostic factors.
Methods
Study population
The records of pediatric patients diagnosed with
idiopathic DCM at Kaohsiung Veterans General
Hospital between October 1990 and July 2004 were
reviewed. Patients with endocardial fibroelastosis,
congenital heart defects, chronic arrhythmia, valvular
heart disease, coronary artery disease, acute myocarditis,
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and heart disease as a result of renal, endocrine,
metabolic or collagen vascular disorders, were excluded
from the study. Eighteen patients met our criteria for
a diagnosis of idiopathic DCM and were classified into
2 groups according to outcome: group 1 comprised
13 patients who died; group 2 comprised 5 patients
who survived. Age at diagnosis, symptoms, treatment,
and clinical course were assessed. Laboratory studies
included chest radiographs, electrocardiograms
(ECGs), Holter monitor findings, echocardiograms,
cardiac catheterization, and endomyocardial biopsy
data. Patients were included in the arrhythmia category
if they had documented arrhythmia (supraventricular
tachycardia, ventricular tachycardia) or extrasystoles
> 30/hour detected by 12-lead ECG or Holter
monitoring.
Statistical analysis
Data were expressed as mean ± standard deviation, or
as median (range). Cumulative survival was determined
by life-table methods. Differences in continuous
variables were analyzed by unpaired Student’s t test.
Differences in categoric variables were evaluated by
Fisher’s exact test. A p value of less than 0.05 was
considered statistically significant.
Results
The age at initial diagnosis for the 18 patients (11
males, 7 females) ranged from fetus to 13 years
(median, 3 months). The follow-up period ranged
from 12 days to 44 months (10.1 ± 13.3 months;
median, 7 months) in group 1, and from 1 to 48
months (26.8 ± 19.1; median, 39 months) in group
2. Thirteen of the 18 patients (72.2%) initially
presented with clinical features of congestive heart
failure. Eight patients (44.4%) had a history of a viral
syndrome within 8 weeks before presentation.
Palpitation occurred in 2 patients (11.1%) and syncope
was reported in 1 (5.6%); none had a family history of
death from DCM.
At initial diagnosis, chest X-ray showed cardiac
enlargement. The mean cardiothoracic ratio was
64.2 ± 7.6%, and mean echocardiographic left
ventricular ejection fraction (LVEF) was 24.3 ± 5.3%.
On follow-up, chest X-ray and echocardiography
showed that 15 patients (13 in group 1; 2 in group 2)
had no documented improvement, whereas 3 patients
in group 2 had documented improvement. LVEF was
21.5 ± 7.4% after a mean of 9 months of follow-up in
group 1, and 30.4 ± 7.6% after a mean of 24 months
of follow-up in group 2.
ECGs were available for all patients. They
demonstrated left ventricular hypertrophy and ST or
T changes in 16 patients (88.9%), left axis deviation
in 4 (22.2%), intraventricular conduction delay in 5
(27.8%), and premature ventricular complexes in 3
(16.7%). Holter monitoring was performed in 15
patients (83.3%) at presentation, and again at follow-
up in 12 (66.7%). In group 1, arrhythmias were
found during illness in 10 (76.9%) patients: atrial
flutter/fibrillation (n = 2); supraventricular
tachycardia (2); frequent premature atrial complexes
(1); nonsustained ventricular tachycardia (< 30
seconds; 1); ventricular couplet (2); and frequent
premature ventricular complexes (2). In group 2, an
arrhythmia was noted in only 1 patient, who had
frequent premature ventricular complexes.
Cardiac catheterization was performed in 10 of the
13 patients in group 1, and in all 5 patients in group
2. In 15 cases, catheterization was not done at diagnosis
but after a period of medical treatment, a median of 10
days after diagnosis. No patient had evidence of
anomalous coronary arteries. Left ventriculography
demonstrated global ventricular dilation and decreased
wall motion in all 15 patients. Mild to moderate mitral
regurgitation was found in 7 patients. Hemodynamic
data for group 1 patients revealed a mean pulmonary
artery pressure (PAP) of 26.5 ± 8.8 mmHg, pulmonary
capillary wedge pressure (PCWP) of 21.1 ± 5.7 mmHg,
left ventricular end diastolic pressure (LVEDP) of
19.2 ± 6.9 mmHg, and cardiac index of 2.4 ± 0.5 L/
min/m2. In group 2, patients had a mean PAP of
29.4 ± 15.6 mmHg, PCWP of 19.3 ± 10.1 mmHg,
LVEDP of 18.1 ± 9.3 mmHg, and cardiac index of
2.8 ± 0.8 L/min/m2. Right ventricular biopsy in 5
patients (3 in group 1; 2 in group 2) demonstrated
various degrees of myocardial fibrosis without active
inflammation (Figure 1).
Figure 1. Cardiac biopsy in a 12-year-old male patient showing
cardiac fibrosis (hematoxylin & eosin, original magnification × 20).
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Medical therapy included diuretics, vasodilators,
beta-blockers, anticoagulants, antiarrhythmic agents,
digitalis, and inotropic agents. Eleven patients died
from severe heart failure while waiting for cardiac
transplantation. One 14-year-old patient underwent
successful cardiac transplantation, but died suddenly 2
years later. Partial left ventriculectomy was used as a
treatment in a 9-month-old patient, but failed. Of 5
survivors, 3 showed improvement in cardiac status
while 2 deteriorated and required cardiac trans-
plantation. In total, 13 patients died, 9 of whom died
within 1 year of the initial diagnosis. The cumula-
tive survival rate was 50% at 1 year and 28% at 4 years
(Figure 2).
Table 1 shows the results of the between-group
statistical analysis. Gender, age at initial diagnosis,
mean PAP, PCWP, LVEDP, and cardiac index were
not predictive of a poor outcome, but the presence of
arrhythmia and low LVEF were.
Discussion
Outcomes for pediatric patients with idiopathic DCM
have varied greatly in previous reports because of
different patient populations and various treatment
programs.4–6,8–10 In this study, clinical diagnoses
were confirmed by echocardiography, cardiac
catheterization data or biopsy. Careful definition of
the study group focused on patients with idiopathic
DCM and excluded those with myocarditis or
endocardial fibroelastosis. Our data showed that half
of the patients died within 1 year of the initial diag-
nosis. This survival rate was lower than that in the
setting of endocardial fibroelastosis,11 but was similar
to those in previous studies that focused on pediatric
patients with idiopathic DCM.4–6
Factors predicting patient outcome have been
analyzed in many previous studies, and include family
history,4,9,12,13 cardiothoracic ratio,3,4,6 age at onset,3,4
presence of arrhythmia,3,10,14,15 cardiac index3,11 and
left ventricular shortening or ejection fractions.6,9,11
Arrhythmia and low LVEF were significant predic-
tors of early death in this series. However, hemody-
namic data were not measured before therapeutic
intervention, and it is likely that the administration of
inotropic agents and vasodilators would have
substantially changed these data. Lastly, regarding the
relatively small number of patients, we would require
more data to make further conclusions about the
clinical value of these potential predictive factors.
The presence of significant atrial or ventricular
arrhythmias may be related to death.4,5,10 Griffin et al4
reported that 71% of their patients who died had
known complex atrial or ventricular arrhythmias or
both. The high mortality rate in their patients may
have been due to the development of arrhythmias.
Our finding that 76.9% of patients who died had a
documented arrhythmia is compatible with these
Figure 2. Survival curve in 18 patients with idiopathic dilated
cardiomyopathy. The highest mortality occurs within 1 year of
initial diagnosis, with a gradual decline in the cumulative survival
rate over the next 3 years.
Table 1. Comparison of prognostic factors in children with idiopathic dilated cardiomyopathy
Group 1 (mortality) Group 2 (survival) p
Male/female (n) 8/5 3/2 NS
Age at diagnosis (mo) 33.7 ± 56.3 18.2 ± 25.2 NS
Follow-up period (mo) 10.1 ± 13.3 26.8 ± 19.1 < 0.05
Arrhythmias (n) 10/13 1/5 < 0.05
LVEF (%) 21.5 ± 7.4 30.4 ± 7.6 < 0.05
Mean PAP (mmHg) 26.5 ± 8.8 29.4 ± 15.6 NS
PCWP (mmHg) 21.1 ± 5.7 19.3 ± 10.1 NS
LVEDP (mmHg) 19.2 ± 6.9 18.1 ± 9.3 NS
Cardiac index (L/min/m2) 2.4 ± 0.5 2.8 ± 0.8 NS
Data shown are mean ± standard deviation (except for gender distribution and arrhythmias). LVEDP = left ventricular end diastolic pressure; LVEF =
left ventricular ejection fraction; NS = not statistically significant; PAP = pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure.
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observations. Thus, attempts to control arrhythmias
with conventional and newer antiarrhythmic agents
are justified. The appearance of symptomatic
arrhythmias may be a clinical marker of deteriorating
myocardial function, and may therefore be useful in
selecting patients who might benefit from cardiac
transplantation. Holter monitoring is recommended
in all patients with idiopathic DCM.
There is no medical treatment that significantly
improves the natural course of idiopathic DCM.
However, intensive afterload reduction,16,17 beta-
blockade,18,19 carnitine,20 coenzyme Q10,21,22 and
intermittent dobutamine and primacor23,24 may lead to
symptomatic control. Appropriate treatment to improve
left ventricular function and control arrhythmias may
benefit such patients while they await cardiac trans-
plantation as it offers the hope of prolonged survi-
val. Currently, the survival of patients who have under-
gone transplantation is almost 90% at 1 year and 75%
at 5 years postoperatively.25
Several limitations need to be specified in this
study. Firstly, this was a retrospective study of patients
seen over a period of more than 10 years. Secondly,
various treatment programs were used, and Holter
monitoring and cardiac catheterization were not
performed in all patients. Thirdly, the patient
population was small and from a tertiary referral cen-
ter, thus resulting in possible bias towards children
with the worst degrees of idiopathic DCM.
The diagnosis of idiopathic DCM in children is
associated with a generally poor prognosis. When
medical therapy fails, heart transplantation is effective
and can provide good medium-term survival. However,
the likelihood of cardiac transplantation is limited
because of the small number of donors in Taiwan.
Such a lack of available donors results in significant
mortality among pediatric patients awaiting trans-
plantation. Advocating organ donation to increase
the size of the organ donor pool is needed to signi-
ficantly reduce the mortality rate in such patients.
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